AstraZeneca, COVID-19, Vaccine, latest, World
More News
-
Oxford pauses Covid-19 vaccine study in kids, awaits more data on blood clot issues
The university said in February it planned to enroll 300 volunteers aged 6-17 years, based in the United Kingdom
-
EU pledges to keep AstraZeneca doses in the bloc for now
Europe should vaccinate enough people in summer to achieve ‘global immunity’ level, says Thierry Breton
-
AstraZeneca may have provided incomplete efficacy data from latest COVID-19 trial: NIAID
AstraZeneca said that its COVID-19 vaccine developed with Oxford University was 79% effective
